Detalhe da pesquisa
1.
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study.
Lancet Oncol
; 20(9): 1239-1251, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31345627
2.
Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial.
Lancet Oncol
; 17(9): 1317-24, 2016 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-27498080
3.
Management of poor-risk metastatic renal cell carcinoma: current approaches, the role of temsirolimus and future directions.
Future Oncol
; 12(4): 533-49, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26606910
4.
Improved survival with MEK inhibition in BRAF-mutated melanoma.
N Engl J Med
; 367(2): 107-14, 2012 Jul 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-22663011
5.
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma.
Cancer Immunol Immunother
; 63(5): 449-58, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24609989
6.
Phase II Study Investigating the Safety and Efficacy of Savolitinib and Durvalumab in Metastatic Papillary Renal Cancer (CALYPSO).
J Clin Oncol
; 41(14): 2493-2502, 2023 05 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36809050
7.
Metastatic renal mucinous tubular and spindle cell carcinoma. Atypical behavior of a rare, morphologically bland tumor.
Ann Diagn Pathol
; 16(5): 407-10, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-21684183
8.
Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study.
Eur J Cancer
; 176: 121-132, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36215945
9.
Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma.
J Clin Oncol
; 39(9): 1020-1028, 2021 03 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33529051
10.
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.
J Clin Oncol
; 39(24): 2656-2666, 2021 08 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33979178
11.
The melanocortin receptor agonist NDP-MSH impairs the allostimulatory function of dendritic cells.
Immunology
; 129(4): 610-9, 2010 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-20074207
12.
Fatigue in renal cell carcinoma: the hidden burden of current targeted therapies.
Oncologist
; 15(11): 1135-46, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-21051659
13.
Sunitinib is superior to interferon alpha with respect to quality of life for patients with renal cell carcinoma.
Nat Clin Pract Oncol
; 6(1): 6-7, 2009 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-19096396
14.
Combination systemic therapy for advanced renal cell carcinoma.
Oncologist
; 14(12): 1218-24, 2009 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-19939892
15.
What is the risk of intracranial bleeding during anti-VEGF therapy?
Neuro Oncol
; 10(4): 624-30, 2008 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-18539884
16.
Drug insight: advances in renal cell carcinoma and the role of targeted therapies.
Nat Clin Pract Oncol
; 4(8): 470-9, 2007 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-17657252
17.
Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies.
Expert Opin Pharmacother
; 18(14): 1477-1490, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28820000
18.
Kinase inhibitors in the treatment of renal cell carcinoma.
Crit Rev Oncol Hematol
; 60(3): 216-26, 2006 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-16860997
19.
Anti-alphaGal-dependent complement-mediated cytotoxicity in metastatic melanoma.
Melanoma Res
; 16(2): 157-63, 2006 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-16567971
20.
Epithelial ovarian cancer metastasizing to the brain: a late manifestation of the disease with an increasing incidence.
J Clin Oncol
; 20(4): 982-6, 2002 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-11844820